Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 5, 2014, Pages 593-603

  Schreiner, Andreas ^a   Lahaye, Marjolein ^b   Peuskens, Joseph ^c   Naber, Dieter ^d,e   Dilbaz, Nesrin ^f   Millet, Bruno ^g   Franco, Manuel A ^h   Rancans, Elmars ⁱ   Turczynski, Jacek ^j   Smeraldi, Enrico ^k   Lara, Elsa ^l   Neznanov, Nikolaj G ^m  

^a JANSSEN CILAG GMBH   (Germany)

^b Janssen Cilag BV Netherlands   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e USKUDAR UNIVERSITY   (Turkey)

^f ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^g Service Hospitalo universitaire de Psychiatrie   (France)

^h Hospital General de Zamora   (Spain)

ⁱ RIGA STRADINS UNIVERSITY   (Latvia)

^j MEDICAL UNIVERSITY OF GDANSK   (Poland)

^k VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^l Unidade de Psicofarmacologia Clínica   (Portugal)

^m Bekhterev St Petersburg Psychoneurological Research Institute   (Russian Federation)

more..

Author keywords

Extended release; Flexible dosing; Paliperidone; Schizophrenia; Switching

Indexed keywords

GLUCOSE; OLANZAPINE; PALIPERIDONE; PROLACTIN; RISPERIDONE;

ADOLESCENT; ADULT; AGED; AMENORRHEA; ARTICLE; BREAST DISCHARGE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GYNECOMASTIA; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MIDDLE AGED; PATIENT SATISFACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SEXUAL DYSFUNCTION; SLEEP QUALITY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; ANXIETY; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; SCHIZOPHRENIA; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 84896270088     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.884071     Document Type: Article

References (26)

1. Hardeman SM, Harding RK, Narasimhan M. Simplifying adherence in schizophrenia. Psychiatr Serv 2010;61:405-8
2. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 2006;67(Suppl 5):9-14
3. Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008;69:817-29
4. Patrick DL, Burns T, Morosini P, et al. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three phase III trials of paliperidone extended-release tablets. Clin Ther 2010;32:275-92
5. Emsley R, Berwaerts J, Eerdekens M, et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008;23:343-56
6. Nyhuis AW, Faries DE, Ascher-Svanum H, et al. Predictors of switching antipsychotic medications in the treatment of schizophrenia. BMC Psychiatry 2010;10:75
7. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
8. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry 2008;69(Suppl 1):4-17
9. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotic. Eur Psychiatry 2010;25(Suppl 2):S12-21
10. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev 2010;12:CD006629
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition. American Psychiatric Association; Washington, DC; 1994
12. Citrome L. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. Expert Opin Drug Metab Toxicol 2012;8:873-88
13. Berwaerts J, Cleton A, Rossenu S, et al. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol 2010;24:1011-18
14. Einarson TR, Hernels ME, Nuamah I, et al. An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate. Ann Pharmacother 2012;46:1322-30
15. Karadayi G, Emiroĝlu B, Üçok A. Relationship of symptomatic remission with quality of life and functionality in patients with schizophrenia. Compr Psychiatry 2011;52:701-7
16. Kleinman L, Lieberman J, Dube S, et al. Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophr Res 2009;107:275-85
17. Nasrallah HA. Atypical antipsychoticinduced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008;13:27-35
18. Schreiner A, Dilbaz N, Kotler M, et al. Paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral olanzapine [poster 188]. Schizophr Res 2010;117:498
19. Schreiner A, Hoeben D, Lahaye M, et al. A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral risperidone [poster 195]. Schizophr Res 2010;117:384
20. Schreiner A, Hoeben D, Lahaye M, et al. A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with aripiprazole [poster 189]. Schizophr Res 2010;117:499
21. Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006;22:1879-92
22. Ereshefsky L, Mascarenas C. Comparison of the effects of different routes of antipsychotic administratrion on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003;64(Suppl 16):18-23
23. Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 2008;172:177-97
24. Jacob R, Chowdhury AN. Metabolic comorbidity in schizophrenia. Indian J Med Sci 2008;62:23-31
25. Kane JM. Addressing side effects from antipsychotic treatment in schizophrenia. J Clin Psychiatry 2011;72:e07
26. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;3:CD006654